Tous Actualités
Suivre
Abonner Resverlogix Corp.

Resverlogix Corp.

Resverlogix Announces a Corporate Update Conference Call & Webcast

Alberta (ots/PRNewswire)

TSX Exchange Symbol: RVX

Resverlogix Corp. today announced they will be hosting a corporate update conference call and webcast with Q&A on September 3rd at 11 am MDT.

Details for the conference call and webcast are as follows:

Link to webcast: http://services.choruscall.ca/links/resverlogix130905.html

Dial in numbers:

Canada & USA Toll Free Dial In: 1-800-319-4610 Outside of Canada & USA call: +1-604-638-5340

About RVX-208

RVX-208 is a first-in-class small molecule that inhibits BET bromodomains. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. These newly produced, functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. ApoA-I may also exert beneficial effects in Alzheimer's disease and Diabetes Mellitus.

About Resverlogix

Resverlogix Corp. is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange . For further information please visit http://www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at http://www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts:

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: +1-403-254-9252
Email:  don@resverlogix.com
(RVX.)

Kenneth Lebioda
SVP Business & Corporate Development
Resverlogix Corp.
Phone: +1-403-254-9252
Email:  ken@resverlogix.com

Plus de actualités: Resverlogix Corp.
Plus de actualités: Resverlogix Corp.
  • 18.04.2013 – 13:02

    Resverlogix Completes Dosing in ASSURE Clinical Trial

    Calgary, Alberta (ots/PRNewswire) - IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease TSX Exchange Symbol: RVX Resverlogix Corp. today announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208, Resverlogix's first-in-class orally active BET-protein inhibitor, using intra-vascular ultrasound (IVUS) in high-risk cardiovascular patients with low ...

  • 08.04.2013 – 13:01

    Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders

    Calgary, Canada (ots/PRNewswire) - Transaction Designed to Enhance Shareholder Value By Unlocking Value of the Epigenetics Platform TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix") today announced that its Board of Directors has approved a proposal to spin-out its subsidiary, RVX Therapeutics Inc. ("RVX Therapeutics"), which will focus on innovative drug research and development by leveraging its epigenetics ...

  • 26.09.2012 – 13:32

    Resverlogix Completes Enrollment in ASSURE Trial

    Calgary, Alberta (ots/PRNewswire) - IVUS data will evaluate plaque regression in patients with Coronary Artery Disease TSX Exchange Symbol: RVX Resverlogix Corp. today announced that it has completed enrollment in ASSURE, a Phase 2b clinical trial targeting high-risk cardiovascular disease patients. ASSURE will evaluate the ability of RVX-208, Resverlogix's BET protein inhibitor, to regress atherosclerotic disease versus ...